The V012 dialysis data is the primary catalyst—watch for sBLA filing details and FDA acceptance timeline in H2 2026. The dilutive offering and cash burn rate (~$55M operating loss in H1 2026) suggest the company will need additional capital within 12-18 months, creating overhang. Monitor hospital adoption of Symvess in trauma and the upcoming CTEV Phase 2a initiation for pipeline valuation.
Price Chart
Executive Summary
Humacyte reported Q2 2026 results with product revenue of $0.4M (up from $0.1M YoY) but a net loss of $36.8M, missing consensus EPS estimates of -$0.10 with a reported GAAP EPS of -$0.16. The key catalyst is the breakthrough V012 Phase 3 dialysis data showing ATEV outperformed AV fistula, supporting a planned sBLA filing in H2 2026, alongside FDA acceptance of the CTEV IND for CABG. However, the company is still in early commercial launch with minimal revenue, high cash burn, and recently conducted a dilutive $57.5M public offering and workforce restructuring, creating a mixed picture of strong pipeline progress versus weak financials.
Key Financial Metrics
Key Facts
- Q2 2026 product revenue was $0.4M, up from $0.1M in Q2 2025.
- GAAP net loss was $36.8M in Q2 2026 vs $37.7M in Q2 2025.
- EPS of -$0.16 missed consensus of -$0.10.
- V012 Phase 3 trial in female dialysis patients met primary endpoint: ATEV provided 91 more catheter-free days vs AV fistula (p=0.00070).
- Plans to file supplemental BLA for dialysis access with FDA in H2 2026.
- FDA accepted IND for CTEV Phase 2a study in CABG, expected to start Q3 2026.
- Raised $57.5M in gross proceeds from a June 2026 public offering.
- Implemented workforce restructuring in May 2026, reducing headcount by ~45 employees, with estimated net savings of $14.3M in 2026.
- Cash, cash equivalents and restricted cash of $80.3M as of June 30, 2026.
Financial Impact
Q2 2026 revenue of $0.4M vs consensus $1.1M; GAAP EPS -$0.16 vs consensus -$0.10; net loss of $36.8M; cash position $80.3M
Risk Factors
- Minimal commercial revenue ($0.4M/quarter) with high cash burn rate.
- Dilutive $57.5M public offering in June 2026 increases share count.
- Workforce restructuring may impact commercial execution.
- Regulatory risk: sBLA for dialysis access not yet filed or approved.
- Long path to profitability with accumulated deficit of $781M.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-094440 |
| Document: tm2622949d1_8k.htm | 0001104659-26-094440 |
| Document: 0001104659-26-094440-index-headers.html | 0001104659-26-094440 |
| Document: 0001104659-26-094440-index.html | 0001104659-26-094440 |
| Document: 0001104659-26-094440.txt | 0001104659-26-094440 |
| 8-K Data (Synthetic) | 0001104659-26-094440 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $0.4400 | awaiting T+60 | — | $0.4010 (−8.86%) |
Aug 19, 2026 9w ago | Press Release | $0.7349 | awaiting T+60 | — | $0.4010 (−45.43%) |
Aug 12, 2026 10w ago | 8-K | $0.6650 | awaiting T+60 | — | $0.4010 (−39.70%) |
Aug 12, 2026 10w ago | Press Release | $0.6650 | awaiting T+60 | — | $0.4010 (−39.70%) |
Aug 7, 2026 11w ago | Press Release | $0.7180 | awaiting T+60 | — | $0.4010 (−44.15%) |
Jun 12, 2026 19w ago | Institutional Cluster | $1.06 $0.5790 | ▼ −45.12% | ▼ −47.90% | $0.4010 (−61.99%) |
Jun 11, 2026 19w ago | 8-K | $1.06 $0.5790 | ▲ +45.12% | ▲ +47.90% | $0.4010 (+61.99%) |
Jun 10, 2026 19w ago | Press Release | $1.08 $0.5949 | ▲ +44.92% | ▲ +48.74% | $0.4010 (+62.87%) |
Jun 10, 2026 19w ago | Press Release | $1.08 $0.5949 | ▲ +44.92% | ▲ +48.74% | $0.4010 (+62.87%) |
Jun 10, 2026 19w ago | Press Release | $1.08 $0.5949 | ▼ −44.92% | ▼ −48.74% | $0.4010 (−62.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers